JP2009545320A5 - - Google Patents

Info

Publication number

JP2009545320A5

JP2009545320A5 JP2009522881A JP2009522881A JP2009545320A5 JP 2009545320 A5 JP2009545320 A5 JP 2009545320A5 JP 2009522881 A JP2009522881 A JP 2009522881A JP 2009522881 A JP2009522881 A JP 2009522881A JP 2009545320 A5 JP2009545320 A5 JP 2009545320A5

Authority

JP

Japan

Prior art keywords

peptide

derivatives

pharmaceutically acceptable

consisting essentially

fragments

Prior art date

2007-08-03

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• Discuss

• 108090000765 processed proteins & peptides Proteins 0.000 claims description 62
• 150000001413 amino acids Chemical class 0.000 claims description 27
• 239000012634 fragment Substances 0.000 claims description 27
• 150000003839 salts Chemical class 0.000 claims description 27
• 238000000034 method Methods 0.000 claims description 16
• 239000008194 pharmaceutical composition Substances 0.000 claims description 12
• 210000000988 bone and bone Anatomy 0.000 claims description 9
• 102000053602 DNA Human genes 0.000 claims description 8
• 108020004511 Recombinant DNA Proteins 0.000 claims description 8
• 208000001132 Osteoporosis Diseases 0.000 claims description 6
• 108020004707 nucleic acids Proteins 0.000 claims description 6
• 102000039446 nucleic acids Human genes 0.000 claims description 6
• 150000007523 nucleic acids Chemical class 0.000 claims description 6
• 238000004519 manufacturing process Methods 0.000 claims description 4
• OXZNHYPGOAWYLT-FISSOZIDSA-N ostabolin Chemical compound C([C@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)C(C)C)[C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1N=CN=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)OC(=O)CC[C@H](NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CCC(O)=O)C(C)C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCCNC(N)=N)C(C)C)C1C=NC=N1 OXZNHYPGOAWYLT-FISSOZIDSA-N 0.000 claims description 4
• 108091033319 polynucleotide Proteins 0.000 claims description 4
• 102000040430 polynucleotide Human genes 0.000 claims description 4
• 239000002157 polynucleotide Substances 0.000 claims description 4
• 208000006386 Bone Resorption Diseases 0.000 claims description 3
• 230000010072 bone remodeling Effects 0.000 claims description 3
• 230000024279 bone resorption Effects 0.000 claims description 3
• 239000003937 drug carrier Substances 0.000 claims description 3
• 230000011164 ossification Effects 0.000 claims description 3
• 241000894006 Bacteria Species 0.000 claims description 2
• 206010065687 Bone loss Diseases 0.000 claims description 2
• 108020004414 DNA Proteins 0.000 claims description 2
• 230000032683 aging Effects 0.000 claims description 2
• 230000001580 bacterial effect Effects 0.000 claims description 2
• 239000007850 fluorescent dye Substances 0.000 claims description 2
• 230000002538 fungal effect Effects 0.000 claims description 2
• 238000001727 in vivo Methods 0.000 claims description 2
• 230000009245 menopause Effects 0.000 claims description 2
• 238000007920 subcutaneous administration Methods 0.000 claims description 2
• 230000003612 virological effect Effects 0.000 claims description 2
• 241000124008 Mammalia Species 0.000 claims 1
• 239000000969 carrier Substances 0.000 claims 1